Insider Selling: Health Catalyst, Inc. (NASDAQ:HCAT) Insider Sells 7,500 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT) insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $8.94, for a total value of $67,050.00. Following the completion of the sale, the insider now owns 236,950 shares of the company’s stock, valued at $2,118,333. This represents a 3.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Health Catalyst Trading Down 12.0 %

Health Catalyst stock traded down $1.08 during trading hours on Tuesday, reaching $7.94. 669,927 shares of the company’s stock traded hands, compared to its average volume of 560,721. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The firm has a market capitalization of $483.15 million, a price-to-earnings ratio of -5.99 and a beta of 1.31. The firm’s 50 day moving average is $8.12 and its 200-day moving average is $7.33. Health Catalyst, Inc. has a fifty-two week low of $5.42 and a fifty-two week high of $11.41.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The business had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. Health Catalyst’s revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.22) earnings per share. On average, analysts predict that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. JPMorgan Chase & Co. raised their target price on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Stephens lifted their price objective on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Citigroup boosted their target price on shares of Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Piper Sandler reiterated an “overweight” rating and set a $12.00 target price (up previously from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Health Catalyst currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.79.

Hedge Funds Weigh In On Health Catalyst

Several hedge funds have recently added to or reduced their stakes in HCAT. Quest Partners LLC bought a new stake in shares of Health Catalyst in the 3rd quarter valued at about $34,000. Nisa Investment Advisors LLC grew its holdings in Health Catalyst by 461.0% during the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after purchasing an additional 5,232 shares during the period. Quarry LP increased its stake in Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after purchasing an additional 2,610 shares in the last quarter. nVerses Capital LLC acquired a new stake in Health Catalyst in the third quarter worth $59,000. Finally, Perfromance Wealth Partners LLC acquired a new stake in Health Catalyst in the second quarter worth $64,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.